Nestlé puts $200M more behind a treatment for peanut allergy
Aimmune’s patients won’t ever be able to eat much or even most of their candy, but every time they open a capsule, they’ll be consuming a product Nestlé helped produce.
Since the immunotherapy company completed its Phase II studies, Nestlé has become one of its largest backers. They invested $145 million in 2016 and $98 million in 2018. And today, days after Aimmune won FDA approval for their peanut allergy drug Palforzia, Nestlé announced a $200 million equity investment. They will now have invested $473 million and command 19.9% of the company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
